CA2427938A1 - Novel temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution, composition and preparation thereof - Google Patents
Novel temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution, composition and preparation thereof Download PDFInfo
- Publication number
- CA2427938A1 CA2427938A1 CA002427938A CA2427938A CA2427938A1 CA 2427938 A1 CA2427938 A1 CA 2427938A1 CA 002427938 A CA002427938 A CA 002427938A CA 2427938 A CA2427938 A CA 2427938A CA 2427938 A1 CA2427938 A1 CA 2427938A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- composition
- group
- composition according
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
Abstract
The present invention relates a biopolymeric liquid aqueous composition for producing self-gelling systems and gels, which comprises: an acidic water- based medium, 0.1 to 10 % by weight of a pH-gelling acid-soluble biopolymer; and 0.1 to 10 % by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, or a water-soluble residue or sequence of the molecule having a basic character and a pKa between 6.0 and 8.4. The liquid composition has a final pH ranging from 5.8 and 7.4, and forms a stable solid and homogeneous gel within a temperature range from 10 to 70 ~C. The present invention also relates to a method for preparing the composition and uses thereof.
Claims (7)
1. ~A polymeric liquid aqueous composition for producing self-gelling systems and gels, which comprises:
a) an acidic water-based medium; and b) 0.1 to 10% by weight of a pH-gelling acid-soluble polymer, with the proviso that said polymer is free of chitosan and chitosan~
derivatives; and c) 0.1 to 10% by weight of a water soluble molecule having a basic character and a pKa between 6.0 and 8.4;
wherein said liquid composition has a frill pH ranging from 5.8 and 7,4, and forms a stable solid and homogeneous gel when heated within a temperature range from 10 to 70°C.
a) an acidic water-based medium; and b) 0.1 to 10% by weight of a pH-gelling acid-soluble polymer, with the proviso that said polymer is free of chitosan and chitosan~
derivatives; and c) 0.1 to 10% by weight of a water soluble molecule having a basic character and a pKa between 6.0 and 8.4;
wherein said liquid composition has a frill pH ranging from 5.8 and 7,4, and forms a stable solid and homogeneous gel when heated within a temperature range from 10 to 70°C.
2. ~A composition according to claim 1, wherein said composition is prepared from organic and/or inorganic acid.
3. ~A composition according to claim 2, wherein the organic and/or inorganic acid is, selected from the group consisting of hydrochloric acid, citric acid, ascorbic acid, lactic acid, lactobionic acid, acetic acid, salicylic acid, formic acid, glutamic acid, phosphoric acid, orthophosphoric acid, and glycerophosphoric acid, or a mixture thereof.
4. ~A composition according to claim 1, wherein said polymer comprises a pH-gelling acid-soluble polysaccharide, polypeptidic or poly(amino acids), or synthetic polymer.
5. ~A composition according to claim 1, wherein said molecule is an organic salt selected from the group consisting of mono-phosphate salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt.
6. ~A composition according to claim 1, wherein said molecule is a salt of polyol selected from the group consisting of mono-phosphate dibasic salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt of polyol, said polyol being selected from the group consisting of glycerol, histidinol, acetol, diethylstil-bestrol, indole-glycerol, sorbitol, ribitol, xylitol, arabinitol, erythritol, inositol, mannitol, glucitol, palmitoyl-glycerol, linoleoyl-glycerol, oleoyl-glycerol, and arachidonoyl-glycerol, or a mixture thereof.
T. A composition according to claim fi, wherein the sah of glycerol is selected from the group consisting of glycerol-2-phosphate, an-glycerol 3-phosphate and L-glycerol-3-phosphate salt, or a mixture thereof.
8. A composition according to claim 1, wherein said molecule is a salt of a sugar selected from the group consisting of mono-phosphate dibasic salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt of a sugar, said sugar being selected from the group consisting of fructose, galactose, ribose, glucose, xylose, rhamnulose, sorbose, erythrulose, deoxy ribose, ketose, mannose, arabinose, fuculose, fructopyranose, ketoglucose, sedoheptulose, trehalose, tagatose, sucrose, allose, threose, xylulose, hexose, methylthio-ribose, and methylthio-deoxy-ribulose, or a mixture thereof.
9. A composition according to claim 1, wherein said molecule is selected from the group consisting of sodium, magnesium or iron salt of glycerol-2-phosphate, sn-glycerol-3-phosphate and L-glycerol-3-phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-phosphate and fructose-6-phosphate, or a mixture thereof.
10. A composition according to claim 1, wherein said molecule is selected from the group consisting of N-(carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis(2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-(N,N-bis(2-hydroxy-ethyl)amino]-2-hydroxypropanesulfonate (DIPSO), N-(2-hydroxyethyl]piperazine-N'-3-propane-sulfonate (EPPS), N-[2-hydroxyethyl]piperazine-N'-4-butane-sulfonate (HEPBS), N-[2-hydroxyethyl]piperazine-N'-2-ethanesulfonate (HEPES), N-[2-hydroxyethyl]
piperazine-N'-2-hydroxypropanesulfonate (HEPSO), 2-(N-morpholino]ethanesulfonate (MES), 4-(N-morpholino]butanesulfonate (MOBS), 3-[N-morpholino]propanesulfonate (MOPS) 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), Piperazine-N,N'-bis[2-ethanesulfonate]
(PIPES), Piperazine-N,N'-bis[2-hydroxypropanesulfonate] (POPSO), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate (TAPSO), and N-tris [hydroxymethyl]methyl-2-aminoethanesulfonate (TES), and derivatives or mixtures thereof.
11. A composition according to claim 1, wherein said molecule is selected from the group consisting of N,N-bis[hydroxyethyl]glycine (BICINE), bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), Glycyl-glycine (GLY-GLY), Triethanolamine (TEA), N-his [hydroxymethyl]methylglycine (TRICINE), and Tris [hydroxymethyl]aminomethane (TRIZMA), and derivatives or mixtures thereof.
12. A composition according to claim 1, wherein said molecule has either one acid group end at least one amino group, or more amino groups than acid groups.
13. A composition according to claim 1, wherein said molecule is an amino-acid residue, an amino-acid sequence or a poly(amino acids) having a basic character and a pKa between 6.0 and 8.4.
14. A composition according to claim 13, wherein said amino acid residue is selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), asparagine (ASN), and glutamine (GLN), or a mixture thereof.
15. A composition according to claim 1, wherein said molecule is an amino acid residue or amino acid derivative selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), and glutamine (GLN), said amino acid residue or amino acid derivative being modified with a radical acetyl, t-butyl, benzyl, benzoyl, ethyl, formyl, or methyl.
16. A composition according to claim 1, wherein said molecule is a sequence, derivative or polymer of at least one amino acid selected from the group consisting of alanine (ALA), histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), glutamine (GLN), glycine (GLY), hydroxyproline (HYP), isoleucine (ILE), leucine (LEU), norleucine (NLE), phenylalanine (PHE), praline (PRO), serine (SER), threonine (THR), tyrosine (TYR), and valine (VAL).
17. A composition according to claim 1, wherein said composition further comprises at feast one other water-soluble polymer other than chitosan.
18. A composition according to claim 1, wherein said at least one other polymer is selected from the group consisting of collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, poly(ethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, and polycaprolactone diols, and derivatives or mixtures thereof.
18. A composition according to claim 1, further comprising a solid particulate or a water-soluble additive.
20. A composition according to claim 1, further comprising a drug or a pharmaceutical agent.
21. A composition according to claim 1, further comprising microorganisms: plant cells, animal tails or human cells dispersed therein.
22. A composition according to claim 1, for use as a carrier for delivering a pharmaceutical agent In situ.
23. A method for, preparing a composition according to claim 1, which comprises the steps of:
a) dissolving a pH-gelling acid-soluble polymer within an aqueous acidic solution of a pH from about 1.0 to about 5.0 to obtain an aqueous polymer composition having a concentration of 0.1 to 10% by weight of said polymer, said polymer being free of chitosan and chitosan derivatives;
b) dissolving 0.1 to 10% by weight of a water soluble molecule having a basic character and a pKa between 6.0 and 8.4 within said aqueous polymer composition to obtain a clear liquid formulation with a pH ranging between 5.8 and 7.4;
c) heating said liquid formulation at a temperature above 30°C to obtain a solid gel, said gel having a pH from about 5:8 to about
T. A composition according to claim fi, wherein the sah of glycerol is selected from the group consisting of glycerol-2-phosphate, an-glycerol 3-phosphate and L-glycerol-3-phosphate salt, or a mixture thereof.
8. A composition according to claim 1, wherein said molecule is a salt of a sugar selected from the group consisting of mono-phosphate dibasic salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt of a sugar, said sugar being selected from the group consisting of fructose, galactose, ribose, glucose, xylose, rhamnulose, sorbose, erythrulose, deoxy ribose, ketose, mannose, arabinose, fuculose, fructopyranose, ketoglucose, sedoheptulose, trehalose, tagatose, sucrose, allose, threose, xylulose, hexose, methylthio-ribose, and methylthio-deoxy-ribulose, or a mixture thereof.
9. A composition according to claim 1, wherein said molecule is selected from the group consisting of sodium, magnesium or iron salt of glycerol-2-phosphate, sn-glycerol-3-phosphate and L-glycerol-3-phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-phosphate and fructose-6-phosphate, or a mixture thereof.
10. A composition according to claim 1, wherein said molecule is selected from the group consisting of N-(carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis(2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-(N,N-bis(2-hydroxy-ethyl)amino]-2-hydroxypropanesulfonate (DIPSO), N-(2-hydroxyethyl]piperazine-N'-3-propane-sulfonate (EPPS), N-[2-hydroxyethyl]piperazine-N'-4-butane-sulfonate (HEPBS), N-[2-hydroxyethyl]piperazine-N'-2-ethanesulfonate (HEPES), N-[2-hydroxyethyl]
piperazine-N'-2-hydroxypropanesulfonate (HEPSO), 2-(N-morpholino]ethanesulfonate (MES), 4-(N-morpholino]butanesulfonate (MOBS), 3-[N-morpholino]propanesulfonate (MOPS) 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), Piperazine-N,N'-bis[2-ethanesulfonate]
(PIPES), Piperazine-N,N'-bis[2-hydroxypropanesulfonate] (POPSO), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate (TAPSO), and N-tris [hydroxymethyl]methyl-2-aminoethanesulfonate (TES), and derivatives or mixtures thereof.
11. A composition according to claim 1, wherein said molecule is selected from the group consisting of N,N-bis[hydroxyethyl]glycine (BICINE), bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), Glycyl-glycine (GLY-GLY), Triethanolamine (TEA), N-his [hydroxymethyl]methylglycine (TRICINE), and Tris [hydroxymethyl]aminomethane (TRIZMA), and derivatives or mixtures thereof.
12. A composition according to claim 1, wherein said molecule has either one acid group end at least one amino group, or more amino groups than acid groups.
13. A composition according to claim 1, wherein said molecule is an amino-acid residue, an amino-acid sequence or a poly(amino acids) having a basic character and a pKa between 6.0 and 8.4.
14. A composition according to claim 13, wherein said amino acid residue is selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), asparagine (ASN), and glutamine (GLN), or a mixture thereof.
15. A composition according to claim 1, wherein said molecule is an amino acid residue or amino acid derivative selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), and glutamine (GLN), said amino acid residue or amino acid derivative being modified with a radical acetyl, t-butyl, benzyl, benzoyl, ethyl, formyl, or methyl.
16. A composition according to claim 1, wherein said molecule is a sequence, derivative or polymer of at least one amino acid selected from the group consisting of alanine (ALA), histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), glutamine (GLN), glycine (GLY), hydroxyproline (HYP), isoleucine (ILE), leucine (LEU), norleucine (NLE), phenylalanine (PHE), praline (PRO), serine (SER), threonine (THR), tyrosine (TYR), and valine (VAL).
17. A composition according to claim 1, wherein said composition further comprises at feast one other water-soluble polymer other than chitosan.
18. A composition according to claim 1, wherein said at least one other polymer is selected from the group consisting of collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, poly(ethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, and polycaprolactone diols, and derivatives or mixtures thereof.
18. A composition according to claim 1, further comprising a solid particulate or a water-soluble additive.
20. A composition according to claim 1, further comprising a drug or a pharmaceutical agent.
21. A composition according to claim 1, further comprising microorganisms: plant cells, animal tails or human cells dispersed therein.
22. A composition according to claim 1, for use as a carrier for delivering a pharmaceutical agent In situ.
23. A method for, preparing a composition according to claim 1, which comprises the steps of:
a) dissolving a pH-gelling acid-soluble polymer within an aqueous acidic solution of a pH from about 1.0 to about 5.0 to obtain an aqueous polymer composition having a concentration of 0.1 to 10% by weight of said polymer, said polymer being free of chitosan and chitosan derivatives;
b) dissolving 0.1 to 10% by weight of a water soluble molecule having a basic character and a pKa between 6.0 and 8.4 within said aqueous polymer composition to obtain a clear liquid formulation with a pH ranging between 5.8 and 7.4;
c) heating said liquid formulation at a temperature above 30°C to obtain a solid gel, said gel having a pH from about 5:8 to about
7.4.
24. The method of claim 23, wherein said aqueous acidic solution is prepared from an . organic or inorganic acid selected from the group consisting of acetic acid, ascorbic acid, glutamic acid, lactic acid, lactobionic acid, salicylic add, phosphoric acid, hydrochloric acid, propionic acid, and formic acid, or a mixture thereof.
25. The method of claim 23, wherein said molecule is an organic salt selected from the group consisting of a mono-phosphate salt, a mono-sulfonate salt, a mono-sulfate salt and a mono-carboxylate salt.
28. The method of claim 23, wherein said molecule is a salt of polyol selected from the group consisting of a mono-phosphate dibasic salt, a mono-sulfonate salt, a mono-sulfate salt and a mono-carboxylate salt of polyol, said polyol being selected from the group consisting of glycerol, histidinol; acetol, diethylstil-bestrol, indole-glycerol, sorbitol, ribitol, xylitol, arabinitol, erythritol, inositol, mannitol, glucitol, palmitoyl-glycerol, linoleoyl-glycerol, oleoyl-glycerol, and arachidonoyl-glycerol, or a mixture thereof.
27. The method of claim 26, wherein said salt of glycerol is selected from the group consisting of glycerol-2-phosphate, sn-glycerol 3-phosphate and L-glycerol-3-phosphate salts, or a mixture thereof.
28. The method of claim 23, wherein said molecule is a salt of sugar selected from the group selected from a mono-phosphate dibasic salt, a mono-sulfonate salt, a mono-sulfate salt and a mono-carboxylate salt of sugar, said sugar being selected from the group consisting of fructose, galactose, ribose, glucose, xylose, rhamnulose, sorbose, erythrulose, deoxy ribose, ketose, mannose, arabinose, fuculose, fructopyranose, ketoglucose, sedoheptulose, trehalose, tagatose, sucrose, allose, threose, xylulose, hexose, methylthio-ribose, and methylthio-deoxy-ribulose, or a mixture thereof.
29. ~The method of claim 23, wherein said molecule is a sodium, magnesium or iron salt of glycerol-2-phosphate, sn-glycerol-3-phosphate and L-glycerol-3-phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-phosphate or fructose-6-phosphate, or a mixture thereof.
30. ~The method of claim 23, wherein said molecule is selected from the group consisting of N-(carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-[N,N-bis(2-hydroxy-ethyl)amino]-2-hydroxypropanesulfonate (DIPSO), N-[2-hydroxyethyl]piperazine-N'-3-propane-sulfonate (EPPS), N-[2-hydroxyethyl]piperazine-N'-4-butane-sulfonate (HEPBS), N-[2-hydroxyethyl]piperazine-N'-2-ethanesulfonate (HEPES), N-[2-hydroxyethyl]
piperazine-N'-2-hydroxypropanesulfonate (HEPSO), 2-[N-morpholino]ethanesulfonate (MES), 4-[N-morpholino]butanesulfonate (MOBS), 3-[N-morpholino]propanesulfonate (MOPS), 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), Piperazine-N,N'-bis[2-ethanesulfonate]
(PIPES), Piperazine-N,N'-bis[2-hydroxypropanesulfonate] (POPSO), 3-(N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate (TAPSO), and N-tris [hydroxymethyl]methyl-2-aminoethanesulfonate (TES), and derivatives or mixtures thereof.
31. The method of claim 23, wherein said molecule is selected from the group consisting of N,N-bis[hydroxyethyl]glycine (BICINE), bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), Glycyl-glycine (GLY-GLY), Triethanolamine (TEA), N-tris [hydroxymethyl]methylglycine (TRICINE), and Tris [hydroxymethyl]aminomethane (TRIZMA), and derivatives or mixtures thereof.
32. The method of claim 23, wherein said molecule has either one acid group and at least one amino group, or more amino groups than acid groups.
33. The method of claim 23, wherein said molecule is an amino-acid residue, an amino-acid sequence or a poly(amino acids) having a basic character and a pKa between 6.O.and 8.4.
34. The method of claim 33, wherein said amino acid residue is selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), asparagine (ASN), glutamine (GLN), or a mixture thereof.
35. The method of claim 33, wherein said molecule is an amino acid residue or amino acid derivative selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), and glutamine (GLN) modified with a radical acetyl, t-butyl, benzyl, benzoyl, ethyl, formyl, or methyl.
38. The method of claim 23, wherein said molecule is a sequence, derivative or polymer of sit least one amino acid selected from the group consisting of alanine (ALA), histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), glutamine (GLN), glycine. (GLY), hyroxyproline (HYP), Isoleucine (ILE), leucine (LEU), norleucine (NLE), phenylalanine (PHE), proline (PRO), serine (SER), threonine (THR), tyrosine (TYR), and vallne (VAL).
37. The method of claim 23, wherein said aqueous polymer composition turns into a gel at a temperature above 10°C.
38. The method of claim 23, wherein said aqueous polymer composition turns into a gel at a temperature above 37°C.
39. The method of claim 23, wherein said polymer solution further comprises a solid particulate additive, said solid particulate additive being added to the polymer solution of step a) or b).
40. The method of claim 23, further comprising another water soluble polymer added to the polymer solution of step a) or b), said other water-soluble polymer being free of chitosan and chitosan derivatives.
41. The method of claim 40, wherein said other polymer is selected from the group consisting of collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide,, polyethylene oxide-co-propylene oxide) copolymers, polyethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, and polycaprolactone diols, or derivatives thereof.
42. The composition of any one of claims 1 to 22 for use in cosmetics, pharmacology, medicine and/or surgery.
43. The composition of any one of claims 1 to 22 for use into an implantable device or an implant for repair, reconstruction and/or replacement of tissues and/or organs.
44. The composition of any one of claims 1 to 22 for use as an implantable, transdermal or dermatological drug delivery system.
45. The composition of any one of claims 1 to 22 for use as an opthalmological implant or a drug delivery system.
48. The composition of any one of claims 1 to 22 for use in cells-loaded artificial matrices for engineering and culture of bioengineered hybrid materials and tissue equivalents.
47. The composition of any one of claims 1 to 22, wherein said composition is loaded with cells selected from the group consisting of chondrocytes (articular cartilage), fibrochondrocytes (meniscus), ligament fibroblasts (ligament), skin fibroblasts (skin), tenocytes (tendons), myofibro-blasts (muscle), mesenchymal stem cells and keratinocytes (skin).
48. The composition of claim 47 for use in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
49. The composition of claim 47 for use in processing and engineering of living artificial substitutes for ligaments, tendons, skin, bone muscles and metabolic organs, either for surgical or laboratory testing applications.
50. The composition of claim 47 for use in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone tissues or skin.
51. The composition of claim 47 for use to induce an ectopic formation of flbrocartilage-like or cartilage-like tissues.
52. The composition of any one of claims 1 to 22 for use as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues.
53. Use of the composition according to any one of claims 1 to 22 in cosmetics, pharmacology, medicine and/or surgery.
54. Use of the composition according to any one of claims 1 to 22 into an implantable device or an implant for repair, reconstruction and/or replacement of tissues and/or organs.
55. Use of the composition according to any one of claims 1 to 22 as an implantable, transdermal or dermatological drug delivery system.
56. Use of the composition according to any one of claims 1 to 22 as an opthalmological implant or a drug delivery system.
57. Use of the composition according to any one of claims 1 to 22 in cells-loaded artificial matrices for engineering and culture of bioengineered hybrid materials and tissue equivalents.
58. Use of the composition of claim 47 in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
59. Use of the composition of claim 47 in processing and engineering of living artificial substitutes for ligaments, tendons, akin, bone muscles and metabolic organs, either for surgical or laboratory testing applications.
60. Use of the composition of claim 47 in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone tissues or skin.
61. Use of the composition of claim 47 to induce an ectopic formation of fibrocartilage-like or cartilage-like tissues.
62. Use of the composition according to any one of claims 1 to 22 as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues.
63. A polymeric liquid aqueous composition for producing self gelling systems and gels, which comprises:
a) an acidic water-based medium; and b) 0.1 to 10% by weight of a pH-gelling acid-soluble polymer; and c) 0.1 to 10% by weight of a water soluble molecule having a basic character and a pKa between 6.0 and 8.4, said water soluble molecule b~ing free of salt of polyol and sugar, wherein said liquid composition has a final pH ranging from 5.8 and 7.4, and forms a stable solid arid homogeneous gel when heated within a temperature range from 10 to 70°C.
64. A composition according to claim 63, wherein said composition is prepared from organic and/or inorganic acid.
65. A composition according to claim 64, wherein the organic and/or inorganic acid is selected from the group consisting of hydrochloric acid, citric acid, ascorbic acid, tactic acid, lactobionic acid, acetic add, salicylic acid, formic acid, glutamic acid, phosphoric acid, orthophosphoric acid, and glycerophosphoric acid, or a mixture thereof.
66. A composition according to claim 63, wherein said polymer comprises a pH-gelling acid-soluble polysaccharide, polypeptidic or poly(amino acids), or synthetic polymer.
67. A composition according to claim 63, wherein said polymer comprises a solution of chitosan, modified chitosan or chitosan derivative, said solution of chitosan being cationic and bearing amino groups.
68. A composition according to claim 63, wherein said molecule is an organic salt selected from the group consisting of mono-phosphate salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt.
69. A composition according to claim 63, wherein said molecule is selected from the group consisting of N-[carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-[N,N-bis(2-hydroxy-ethyl)amino]-2-hydroxypropanesulfonate (DIPSO), N-[2-hydroxyethyl]piperazine-N'-3-propane-sulfonate (EPPS), N-[2-hydroxyethyl]piperazine-N'-4-butane-sulfonate (HEPBS), N-[2-hydroxyethyl]piperazine-N'-2-ethanesulfonate (HEPES), N-[2-hydroxyethy]
piperazine-N'-2-hydroxypropanesulfonate (HEPSO), 2-[N-morpholino]ethanesulfonate (MES), 4-[N-morpholino]butanesulfonate (MOBS); 3-[N-morpholino]propanesulfonate (MOPS), 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), Piperazine-N,N'-bis[2-ethanesulfonate]
(PIPES), Piperazine-N,N'-bis[2-hydroxypropanesulfonate] (POPSO), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate. (TAPSO), and N-tris [hydroxymethyl]methyl-2-aminoethanesulfonate (TES), and derivatives or mixtures thereof.
70. A composition according to claim 83, wherein said molecule is selected from the group consisting of N;N-bis[hydroxyethyl]glycine (BICINE), bis (2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), Glycyl-glycine (GLY-GLY), Triethanolamine (TEA), N-Iris (hydroxymethyl]methylglycine (TRICINE), and Tris [hydroxymethyl]aminomethane (TRIZMA), and derivatives or mixtures thereof.
-29a-71. A composition according to claim 63, wherein said molecule has either one acid group and at least ore amino group, or more amino groups than acid groups.
72. A composition according to claim 63, wherein said molecule is an amino-acid residue, an amino-acid sequence or a poly(amino acids) having a basic character and a pKa between 6.0 and 8.4.
73. A composition according to claim 72, wherein said amino acid residue is selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), asparagine (ASN), and glutamine (GLN), or a mixture thereof.
74. A composition according to claim 83, wherein said molecule is an amino acid residue or amino acid derivative selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), end glutamine (GLN), said amino acid residue or amino acid derivative being modified with a radical acetyl, t-butyl, benzyl, benzoyl, ethyl, formyl, or methyl.
75. A composition according to claim 63, wherein said molecule is a sequence, derivative or polymer of at least one amino acid selected from the group consisting of alanine (ALA), histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), glutamine (GLN), glycine (GLY), hydroxyproline (HYP), isoleucine (ILE), leucine (LEU), norleucine (NLE), phenylalanine (PHE), proline (PRO), serine (SER), threonine (THR), tyrosine (TYR), end valine (VAL).
76. A composition according to claim 63, wherein said composition further comprises at least one other water soluble polymer.
77. A composition according to claim 63, wherein said at least one other polymer is selected from the group consisting of collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, -29b-polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, polyethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, and polycaprolactone diols, and derivatives or mixtures thereof.
78. A composition according to claim 63, further comprising a solid particulate or a water soluble additive.
79. A composition according to claim 63, further comprising a drug or a pharmaceutical agent.
80. A composition according to claim 63, further comprising microorganisms, plant cells, animal cells or human cells dispersed therein.
81. A composition according to claim 63, for use as a carrier for delivering a pharmaceutical agent in situ.
82. A method for preparing a composition according to claim 63, which comprises the stops of:
a) dissolving a pH-gelling acid-soluble polymer within an aqueous acidic solution of a pH from about 1.0 to about 6.0 to obtain an aqueous polymer composition having a concentration of 0.1 to 10% by weight of said polymer, b) dissolving 0,1 to 10% by weight of a water soluble molecule having a basic character and a pKa between 6.0 and 8.4 within said aqueous polymer composition to obtain a clear liquid formulation with a pH ranging between 5.8 and 7.4, said water soluble molecule being free of salt of polyol and sugar, c) heating said liquid formulation at a temperature above 30°C to obtain a solid gel, said gel having a pH from about 5.8 to about 7.4.
83. The method of claim 82, wherein said aqueous acidic solution is prepared from an organic or inorganic acid selected from the group consisting of acetic acid, ascorbic acid, glutamic acid, lactic acid, lactobionic -29c-acid, salicylic acid, phosphoric acid, hydrochloric acid, propionic acid, and formic acid, or a mixture thereof.
84. The method of claim 82, wherein said polymer is a chitosan or a chitosan derivative, with a degree of deacetylation ranging from 35 to 99%.
85. The method of claim 82, wherein said molecule is an organic salt selected from the group consisting of a mono-phosphate salt, a mono-sulfonate salt, a mono-sulfate salt and a mono-carboxylate salt.
86. The method of claim 82, wherein said molecule is selected from the group consisting of N-[carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-[N,N-bis(2-hydroxy-ethylamino]-2-hydroxypropanesulfonate (DIPSO), N-[2-hydroxyethyl]piperazine-N'-3-propane-sulfonate (EPPS), N-(2-hydroxyethyl]piperazine-N'-4-butane-sulfonate (HEPBS), N-[2-hydroxyethyl]piperazine-N'-2-ethanesulfonate (HEPES), N-[2-hydroxyethyl]
piperazine-N'-2-hydroxypropanesulfonate (HEPSO), 2-[N-morpholino]ethanesulfonate (MES), 4-[N-morpholino]butanesulfonate (MOBS), 3-[N-morpholino)propanesulfonate (MOPS), 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), Piperazine-N,N'-bis[2-ethanesulfonate]
(PIPES), Piperazine-N,N'-bis[2-hydroxypropanesulfonate] (POPSO), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate (TAPSO), and N-tris [hydroxymethyl]methyl-2-aminoethanesulfonate (TES), and derivatives or mixtures thereof.
87. The method of claim 82, wherein said molecule is selected from the group consisting of N,N-bis[hydroxyethyl]glycine (BICINE), bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), Glycyl-glycine (GLY-GLY), Triethanolamine (TEA), N-tris [hydroxymethyl]methylglycine (TRICINE), and Tris [hydroxymethyl]aminomethane (TRIZMA), and derivatives or mixtures thereof.
88. The method of claim 82, wherein said molecule has either one acid group and at least one amino group, or more amino groups than acid groups.
-29d-89. The method of claim 82, wherein said molecule is an amino-acid residue, an amino-acid sequence or a poly(amino acids) having a basic character and a pKa between 6.0 and 8.4.
90. The method of claim 89, wherein said amino acid residue is selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), asparagine (ASN), glutamine (GLN), or a mixture thereof.
99. The method of claim 89, wherein said molecule is an amino acid residue or amino acid derivative selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), and glutamine (GLN) modified with a radical acetyl, t-butyl, benzyl, benzoyl, ethyl, formyl, or methyl.
92. The method of claim 82, wherein said molecule is a sequence, derivative or polymer of at least one amino acid selected from the group consisting of alanine (ALA), histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), glutamine (GIN), glycine (GLY), hyroxyproline (HYP), isoleucine (ILE), leucine (LEU), norleucine (NLE), phenylalanine (PHE), praline (PRO), serine (SER), threonine (THR), tyrosine (TYR), and valine (VAL).
93. The method of claim 82, wherein said aqueous polymer composition turns into a gel at a temperature above 10°C.
94. The method of claim 82, wherein said aqueous polymer composition turns into a gel at a temperature above 37°C.
95. The method of claim 82, wherein said polymer solution further comprises a solid particulate additive, said solid particulate additive being added to the polymer solution of step a) or b).
98. The method of claim 82, further comprising another water soluble polymer added to the polymer solution of step a) or b).
-29e-97. The method of claim 96, wherein said other polymer is selected from the group consisting of collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, poly(ethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, and polycaprolactone diols, or derivatives thereof.
98. The composition of any one of claims 63 to 81 for use in cosmetics.
pharmacology, medicine and/or surgery.
99. The composition of any one of claims 63 to 81 for use into an implantable device or an implant for repair, reconstruction and/or replacement of tissues and/or organs.
100. The composition of any one of claims 63 to 81 for use as an implantable, transdermal or dermatological drug delivery system.
101. The composition of any one of claims 83 to 81 for use as an opthalmological implant or a drug delivery system.
102. The composition of any one of claims 63 to 81 for use in cells-loaded artificial matrices for engineering and culture of bioengineered hybrid materials and tissue equivalents, 103. The composition of any one of claims 63 to 81, wherein said composition is loaded with cells selected from the group consisting of chondrocytes (articular cartilage), fibrochondrocytes (meniscus), ligament fibroblasts (ligament), skin fibroblasts (skin), tenocytes (tendons), myofibro-blasts (muscle), mesenchymal stem coils and keratinocytes (skin).
104. The composition of claim 103 for use in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
-29f-105. The composition of claim 103 for use in processing and engineering of living artificial substitutes for ligaments; tendons, skin, bone muscles and metabolic organs, either for surgical or laboratory testing applications.
106. The composition of claim 103 for use in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone tissues or skin.
107. The composition of claim 103 for use to induce an ectopic formation of fibrocartilage-like or cartilage-like tissues.
108. The composition of any one of claims 63 to 81 for use as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues.
109. Use of the composition according to any one of claims 83 to 81 in cosmetics, pharmacology, medicine and/or surgery.
190. Use of the composition according to any one of claims 63 to 81 into an implantable device or an implant for repair, reconstruction and/or replacement of tissues and/or organs.
111. Use of the composition according to any one of claims 63 to 81 as an implantable, transdermal or dermatological drug delivery system.
112. Use of the composition according to any one of claims 63 to 81 as an opthalmological implant or a drug delivery system.
113. Use of the composition according to any one of claims 63 to 81 in cells-loaded artificial matrices for engineering and culture of bioengineered hybrid materials and tissue equivalents.
114. Use of the composition of claim 103 in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
-29g-115. Use of the composition of claim 103 in processing and engineering of living artificial substitutes for ligaments, tendons, skin, bone muscles and metabolic organs, either for surgical or laboratory testing applications.
116. Use of the composition of claim 103 in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone tissues or skin.
117. Use of the composition of claim 103 to induce an ectopic formation of fibrocartilage-like or cartilage-like tissues.
118. Use of the composition according to any one of claims 63 to 81 as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues.
24. The method of claim 23, wherein said aqueous acidic solution is prepared from an . organic or inorganic acid selected from the group consisting of acetic acid, ascorbic acid, glutamic acid, lactic acid, lactobionic acid, salicylic add, phosphoric acid, hydrochloric acid, propionic acid, and formic acid, or a mixture thereof.
25. The method of claim 23, wherein said molecule is an organic salt selected from the group consisting of a mono-phosphate salt, a mono-sulfonate salt, a mono-sulfate salt and a mono-carboxylate salt.
28. The method of claim 23, wherein said molecule is a salt of polyol selected from the group consisting of a mono-phosphate dibasic salt, a mono-sulfonate salt, a mono-sulfate salt and a mono-carboxylate salt of polyol, said polyol being selected from the group consisting of glycerol, histidinol; acetol, diethylstil-bestrol, indole-glycerol, sorbitol, ribitol, xylitol, arabinitol, erythritol, inositol, mannitol, glucitol, palmitoyl-glycerol, linoleoyl-glycerol, oleoyl-glycerol, and arachidonoyl-glycerol, or a mixture thereof.
27. The method of claim 26, wherein said salt of glycerol is selected from the group consisting of glycerol-2-phosphate, sn-glycerol 3-phosphate and L-glycerol-3-phosphate salts, or a mixture thereof.
28. The method of claim 23, wherein said molecule is a salt of sugar selected from the group selected from a mono-phosphate dibasic salt, a mono-sulfonate salt, a mono-sulfate salt and a mono-carboxylate salt of sugar, said sugar being selected from the group consisting of fructose, galactose, ribose, glucose, xylose, rhamnulose, sorbose, erythrulose, deoxy ribose, ketose, mannose, arabinose, fuculose, fructopyranose, ketoglucose, sedoheptulose, trehalose, tagatose, sucrose, allose, threose, xylulose, hexose, methylthio-ribose, and methylthio-deoxy-ribulose, or a mixture thereof.
29. ~The method of claim 23, wherein said molecule is a sodium, magnesium or iron salt of glycerol-2-phosphate, sn-glycerol-3-phosphate and L-glycerol-3-phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-phosphate or fructose-6-phosphate, or a mixture thereof.
30. ~The method of claim 23, wherein said molecule is selected from the group consisting of N-(carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-[N,N-bis(2-hydroxy-ethyl)amino]-2-hydroxypropanesulfonate (DIPSO), N-[2-hydroxyethyl]piperazine-N'-3-propane-sulfonate (EPPS), N-[2-hydroxyethyl]piperazine-N'-4-butane-sulfonate (HEPBS), N-[2-hydroxyethyl]piperazine-N'-2-ethanesulfonate (HEPES), N-[2-hydroxyethyl]
piperazine-N'-2-hydroxypropanesulfonate (HEPSO), 2-[N-morpholino]ethanesulfonate (MES), 4-[N-morpholino]butanesulfonate (MOBS), 3-[N-morpholino]propanesulfonate (MOPS), 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), Piperazine-N,N'-bis[2-ethanesulfonate]
(PIPES), Piperazine-N,N'-bis[2-hydroxypropanesulfonate] (POPSO), 3-(N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate (TAPSO), and N-tris [hydroxymethyl]methyl-2-aminoethanesulfonate (TES), and derivatives or mixtures thereof.
31. The method of claim 23, wherein said molecule is selected from the group consisting of N,N-bis[hydroxyethyl]glycine (BICINE), bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), Glycyl-glycine (GLY-GLY), Triethanolamine (TEA), N-tris [hydroxymethyl]methylglycine (TRICINE), and Tris [hydroxymethyl]aminomethane (TRIZMA), and derivatives or mixtures thereof.
32. The method of claim 23, wherein said molecule has either one acid group and at least one amino group, or more amino groups than acid groups.
33. The method of claim 23, wherein said molecule is an amino-acid residue, an amino-acid sequence or a poly(amino acids) having a basic character and a pKa between 6.O.and 8.4.
34. The method of claim 33, wherein said amino acid residue is selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), asparagine (ASN), glutamine (GLN), or a mixture thereof.
35. The method of claim 33, wherein said molecule is an amino acid residue or amino acid derivative selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), and glutamine (GLN) modified with a radical acetyl, t-butyl, benzyl, benzoyl, ethyl, formyl, or methyl.
38. The method of claim 23, wherein said molecule is a sequence, derivative or polymer of sit least one amino acid selected from the group consisting of alanine (ALA), histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), glutamine (GLN), glycine. (GLY), hyroxyproline (HYP), Isoleucine (ILE), leucine (LEU), norleucine (NLE), phenylalanine (PHE), proline (PRO), serine (SER), threonine (THR), tyrosine (TYR), and vallne (VAL).
37. The method of claim 23, wherein said aqueous polymer composition turns into a gel at a temperature above 10°C.
38. The method of claim 23, wherein said aqueous polymer composition turns into a gel at a temperature above 37°C.
39. The method of claim 23, wherein said polymer solution further comprises a solid particulate additive, said solid particulate additive being added to the polymer solution of step a) or b).
40. The method of claim 23, further comprising another water soluble polymer added to the polymer solution of step a) or b), said other water-soluble polymer being free of chitosan and chitosan derivatives.
41. The method of claim 40, wherein said other polymer is selected from the group consisting of collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide,, polyethylene oxide-co-propylene oxide) copolymers, polyethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, and polycaprolactone diols, or derivatives thereof.
42. The composition of any one of claims 1 to 22 for use in cosmetics, pharmacology, medicine and/or surgery.
43. The composition of any one of claims 1 to 22 for use into an implantable device or an implant for repair, reconstruction and/or replacement of tissues and/or organs.
44. The composition of any one of claims 1 to 22 for use as an implantable, transdermal or dermatological drug delivery system.
45. The composition of any one of claims 1 to 22 for use as an opthalmological implant or a drug delivery system.
48. The composition of any one of claims 1 to 22 for use in cells-loaded artificial matrices for engineering and culture of bioengineered hybrid materials and tissue equivalents.
47. The composition of any one of claims 1 to 22, wherein said composition is loaded with cells selected from the group consisting of chondrocytes (articular cartilage), fibrochondrocytes (meniscus), ligament fibroblasts (ligament), skin fibroblasts (skin), tenocytes (tendons), myofibro-blasts (muscle), mesenchymal stem cells and keratinocytes (skin).
48. The composition of claim 47 for use in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
49. The composition of claim 47 for use in processing and engineering of living artificial substitutes for ligaments, tendons, skin, bone muscles and metabolic organs, either for surgical or laboratory testing applications.
50. The composition of claim 47 for use in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone tissues or skin.
51. The composition of claim 47 for use to induce an ectopic formation of flbrocartilage-like or cartilage-like tissues.
52. The composition of any one of claims 1 to 22 for use as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues.
53. Use of the composition according to any one of claims 1 to 22 in cosmetics, pharmacology, medicine and/or surgery.
54. Use of the composition according to any one of claims 1 to 22 into an implantable device or an implant for repair, reconstruction and/or replacement of tissues and/or organs.
55. Use of the composition according to any one of claims 1 to 22 as an implantable, transdermal or dermatological drug delivery system.
56. Use of the composition according to any one of claims 1 to 22 as an opthalmological implant or a drug delivery system.
57. Use of the composition according to any one of claims 1 to 22 in cells-loaded artificial matrices for engineering and culture of bioengineered hybrid materials and tissue equivalents.
58. Use of the composition of claim 47 in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
59. Use of the composition of claim 47 in processing and engineering of living artificial substitutes for ligaments, tendons, akin, bone muscles and metabolic organs, either for surgical or laboratory testing applications.
60. Use of the composition of claim 47 in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone tissues or skin.
61. Use of the composition of claim 47 to induce an ectopic formation of fibrocartilage-like or cartilage-like tissues.
62. Use of the composition according to any one of claims 1 to 22 as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues.
63. A polymeric liquid aqueous composition for producing self gelling systems and gels, which comprises:
a) an acidic water-based medium; and b) 0.1 to 10% by weight of a pH-gelling acid-soluble polymer; and c) 0.1 to 10% by weight of a water soluble molecule having a basic character and a pKa between 6.0 and 8.4, said water soluble molecule b~ing free of salt of polyol and sugar, wherein said liquid composition has a final pH ranging from 5.8 and 7.4, and forms a stable solid arid homogeneous gel when heated within a temperature range from 10 to 70°C.
64. A composition according to claim 63, wherein said composition is prepared from organic and/or inorganic acid.
65. A composition according to claim 64, wherein the organic and/or inorganic acid is selected from the group consisting of hydrochloric acid, citric acid, ascorbic acid, tactic acid, lactobionic acid, acetic add, salicylic acid, formic acid, glutamic acid, phosphoric acid, orthophosphoric acid, and glycerophosphoric acid, or a mixture thereof.
66. A composition according to claim 63, wherein said polymer comprises a pH-gelling acid-soluble polysaccharide, polypeptidic or poly(amino acids), or synthetic polymer.
67. A composition according to claim 63, wherein said polymer comprises a solution of chitosan, modified chitosan or chitosan derivative, said solution of chitosan being cationic and bearing amino groups.
68. A composition according to claim 63, wherein said molecule is an organic salt selected from the group consisting of mono-phosphate salt, mono-sulfonate salt, mono-sulfate salt and mono-carboxylate salt.
69. A composition according to claim 63, wherein said molecule is selected from the group consisting of N-[carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-[N,N-bis(2-hydroxy-ethyl)amino]-2-hydroxypropanesulfonate (DIPSO), N-[2-hydroxyethyl]piperazine-N'-3-propane-sulfonate (EPPS), N-[2-hydroxyethyl]piperazine-N'-4-butane-sulfonate (HEPBS), N-[2-hydroxyethyl]piperazine-N'-2-ethanesulfonate (HEPES), N-[2-hydroxyethy]
piperazine-N'-2-hydroxypropanesulfonate (HEPSO), 2-[N-morpholino]ethanesulfonate (MES), 4-[N-morpholino]butanesulfonate (MOBS); 3-[N-morpholino]propanesulfonate (MOPS), 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), Piperazine-N,N'-bis[2-ethanesulfonate]
(PIPES), Piperazine-N,N'-bis[2-hydroxypropanesulfonate] (POPSO), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate. (TAPSO), and N-tris [hydroxymethyl]methyl-2-aminoethanesulfonate (TES), and derivatives or mixtures thereof.
70. A composition according to claim 83, wherein said molecule is selected from the group consisting of N;N-bis[hydroxyethyl]glycine (BICINE), bis (2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), Glycyl-glycine (GLY-GLY), Triethanolamine (TEA), N-Iris (hydroxymethyl]methylglycine (TRICINE), and Tris [hydroxymethyl]aminomethane (TRIZMA), and derivatives or mixtures thereof.
-29a-71. A composition according to claim 63, wherein said molecule has either one acid group and at least ore amino group, or more amino groups than acid groups.
72. A composition according to claim 63, wherein said molecule is an amino-acid residue, an amino-acid sequence or a poly(amino acids) having a basic character and a pKa between 6.0 and 8.4.
73. A composition according to claim 72, wherein said amino acid residue is selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), asparagine (ASN), and glutamine (GLN), or a mixture thereof.
74. A composition according to claim 83, wherein said molecule is an amino acid residue or amino acid derivative selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), end glutamine (GLN), said amino acid residue or amino acid derivative being modified with a radical acetyl, t-butyl, benzyl, benzoyl, ethyl, formyl, or methyl.
75. A composition according to claim 63, wherein said molecule is a sequence, derivative or polymer of at least one amino acid selected from the group consisting of alanine (ALA), histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), glutamine (GLN), glycine (GLY), hydroxyproline (HYP), isoleucine (ILE), leucine (LEU), norleucine (NLE), phenylalanine (PHE), proline (PRO), serine (SER), threonine (THR), tyrosine (TYR), end valine (VAL).
76. A composition according to claim 63, wherein said composition further comprises at least one other water soluble polymer.
77. A composition according to claim 63, wherein said at least one other polymer is selected from the group consisting of collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, -29b-polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, polyethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, and polycaprolactone diols, and derivatives or mixtures thereof.
78. A composition according to claim 63, further comprising a solid particulate or a water soluble additive.
79. A composition according to claim 63, further comprising a drug or a pharmaceutical agent.
80. A composition according to claim 63, further comprising microorganisms, plant cells, animal cells or human cells dispersed therein.
81. A composition according to claim 63, for use as a carrier for delivering a pharmaceutical agent in situ.
82. A method for preparing a composition according to claim 63, which comprises the stops of:
a) dissolving a pH-gelling acid-soluble polymer within an aqueous acidic solution of a pH from about 1.0 to about 6.0 to obtain an aqueous polymer composition having a concentration of 0.1 to 10% by weight of said polymer, b) dissolving 0,1 to 10% by weight of a water soluble molecule having a basic character and a pKa between 6.0 and 8.4 within said aqueous polymer composition to obtain a clear liquid formulation with a pH ranging between 5.8 and 7.4, said water soluble molecule being free of salt of polyol and sugar, c) heating said liquid formulation at a temperature above 30°C to obtain a solid gel, said gel having a pH from about 5.8 to about 7.4.
83. The method of claim 82, wherein said aqueous acidic solution is prepared from an organic or inorganic acid selected from the group consisting of acetic acid, ascorbic acid, glutamic acid, lactic acid, lactobionic -29c-acid, salicylic acid, phosphoric acid, hydrochloric acid, propionic acid, and formic acid, or a mixture thereof.
84. The method of claim 82, wherein said polymer is a chitosan or a chitosan derivative, with a degree of deacetylation ranging from 35 to 99%.
85. The method of claim 82, wherein said molecule is an organic salt selected from the group consisting of a mono-phosphate salt, a mono-sulfonate salt, a mono-sulfate salt and a mono-carboxylate salt.
86. The method of claim 82, wherein said molecule is selected from the group consisting of N-[carbamoylmethyl]-2-aminoethane sulfonate (ACES), N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonate (BES), 3-[N,N-bis(2-hydroxy-ethylamino]-2-hydroxypropanesulfonate (DIPSO), N-[2-hydroxyethyl]piperazine-N'-3-propane-sulfonate (EPPS), N-(2-hydroxyethyl]piperazine-N'-4-butane-sulfonate (HEPBS), N-[2-hydroxyethyl]piperazine-N'-2-ethanesulfonate (HEPES), N-[2-hydroxyethyl]
piperazine-N'-2-hydroxypropanesulfonate (HEPSO), 2-[N-morpholino]ethanesulfonate (MES), 4-[N-morpholino]butanesulfonate (MOBS), 3-[N-morpholino)propanesulfonate (MOPS), 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), Piperazine-N,N'-bis[2-ethanesulfonate]
(PIPES), Piperazine-N,N'-bis[2-hydroxypropanesulfonate] (POPSO), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonate (TAPSO), and N-tris [hydroxymethyl]methyl-2-aminoethanesulfonate (TES), and derivatives or mixtures thereof.
87. The method of claim 82, wherein said molecule is selected from the group consisting of N,N-bis[hydroxyethyl]glycine (BICINE), bis [2-hydroxyethyl]iminotris [hydroxymethyl]methane (BIS-TRIS), Glycyl-glycine (GLY-GLY), Triethanolamine (TEA), N-tris [hydroxymethyl]methylglycine (TRICINE), and Tris [hydroxymethyl]aminomethane (TRIZMA), and derivatives or mixtures thereof.
88. The method of claim 82, wherein said molecule has either one acid group and at least one amino group, or more amino groups than acid groups.
-29d-89. The method of claim 82, wherein said molecule is an amino-acid residue, an amino-acid sequence or a poly(amino acids) having a basic character and a pKa between 6.0 and 8.4.
90. The method of claim 89, wherein said amino acid residue is selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), asparagine (ASN), glutamine (GLN), or a mixture thereof.
99. The method of claim 89, wherein said molecule is an amino acid residue or amino acid derivative selected from the group consisting of histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), and glutamine (GLN) modified with a radical acetyl, t-butyl, benzyl, benzoyl, ethyl, formyl, or methyl.
92. The method of claim 82, wherein said molecule is a sequence, derivative or polymer of at least one amino acid selected from the group consisting of alanine (ALA), histidine (HIS), arginine (ARG), lysine (LYS), aspartic acid (ASP), glutamine (GIN), glycine (GLY), hyroxyproline (HYP), isoleucine (ILE), leucine (LEU), norleucine (NLE), phenylalanine (PHE), praline (PRO), serine (SER), threonine (THR), tyrosine (TYR), and valine (VAL).
93. The method of claim 82, wherein said aqueous polymer composition turns into a gel at a temperature above 10°C.
94. The method of claim 82, wherein said aqueous polymer composition turns into a gel at a temperature above 37°C.
95. The method of claim 82, wherein said polymer solution further comprises a solid particulate additive, said solid particulate additive being added to the polymer solution of step a) or b).
98. The method of claim 82, further comprising another water soluble polymer added to the polymer solution of step a) or b).
-29e-97. The method of claim 96, wherein said other polymer is selected from the group consisting of collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propyl cellulose, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide) copolymers, poly(ethylene oxide-co-propylene oxide-co-ethylene oxide) copolymers, polyvinyl alcohol, and polycaprolactone diols, or derivatives thereof.
98. The composition of any one of claims 63 to 81 for use in cosmetics.
pharmacology, medicine and/or surgery.
99. The composition of any one of claims 63 to 81 for use into an implantable device or an implant for repair, reconstruction and/or replacement of tissues and/or organs.
100. The composition of any one of claims 63 to 81 for use as an implantable, transdermal or dermatological drug delivery system.
101. The composition of any one of claims 83 to 81 for use as an opthalmological implant or a drug delivery system.
102. The composition of any one of claims 63 to 81 for use in cells-loaded artificial matrices for engineering and culture of bioengineered hybrid materials and tissue equivalents, 103. The composition of any one of claims 63 to 81, wherein said composition is loaded with cells selected from the group consisting of chondrocytes (articular cartilage), fibrochondrocytes (meniscus), ligament fibroblasts (ligament), skin fibroblasts (skin), tenocytes (tendons), myofibro-blasts (muscle), mesenchymal stem coils and keratinocytes (skin).
104. The composition of claim 103 for use in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
-29f-105. The composition of claim 103 for use in processing and engineering of living artificial substitutes for ligaments; tendons, skin, bone muscles and metabolic organs, either for surgical or laboratory testing applications.
106. The composition of claim 103 for use in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone tissues or skin.
107. The composition of claim 103 for use to induce an ectopic formation of fibrocartilage-like or cartilage-like tissues.
108. The composition of any one of claims 63 to 81 for use as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues.
109. Use of the composition according to any one of claims 83 to 81 in cosmetics, pharmacology, medicine and/or surgery.
190. Use of the composition according to any one of claims 63 to 81 into an implantable device or an implant for repair, reconstruction and/or replacement of tissues and/or organs.
111. Use of the composition according to any one of claims 63 to 81 as an implantable, transdermal or dermatological drug delivery system.
112. Use of the composition according to any one of claims 63 to 81 as an opthalmological implant or a drug delivery system.
113. Use of the composition according to any one of claims 63 to 81 in cells-loaded artificial matrices for engineering and culture of bioengineered hybrid materials and tissue equivalents.
114. Use of the composition of claim 103 in culturing and engineering of artificial articular cartilage and cartilageous tissues and organs, either for surgical or laboratory testing applications.
-29g-115. Use of the composition of claim 103 in processing and engineering of living artificial substitutes for ligaments, tendons, skin, bone muscles and metabolic organs, either for surgical or laboratory testing applications.
116. Use of the composition of claim 103 in living substitutes for the replacement of articular cartilages, fibrocartilages, cartilageous organs, ligaments, tendons, bone tissues or skin.
117. Use of the composition of claim 103 to induce an ectopic formation of fibrocartilage-like or cartilage-like tissues.
118. Use of the composition according to any one of claims 63 to 81 as an injectable or implantable gel biomaterial which acts as supports, carriers, reconstructive devices or substitutes for the formation in situ of bone-like, fibrocartilage-like or cartilage-like tissues.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2685349A CA2685349C (en) | 1999-11-15 | 2000-11-10 | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16564199P | 1999-11-15 | 1999-11-15 | |
US60/165,641 | 1999-11-15 | ||
PCT/CA2000/001341 WO2001036000A1 (en) | 1999-11-15 | 2000-11-10 | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2685349A Division CA2685349C (en) | 1999-11-15 | 2000-11-10 | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2427938A1 true CA2427938A1 (en) | 2001-05-25 |
CA2427938C CA2427938C (en) | 2010-02-16 |
Family
ID=22599806
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2685349A Expired - Lifetime CA2685349C (en) | 1999-11-15 | 2000-11-10 | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
CA2427938A Expired - Lifetime CA2427938C (en) | 1999-11-15 | 2000-11-10 | Novel temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution, composition and preparation thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2685349A Expired - Lifetime CA2685349C (en) | 1999-11-15 | 2000-11-10 | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
Country Status (7)
Country | Link |
---|---|
US (1) | US8920842B2 (en) |
EP (1) | EP1229940B1 (en) |
AU (1) | AU1375301A (en) |
CA (2) | CA2685349C (en) |
DK (1) | DK1229940T3 (en) |
ES (1) | ES2491866T3 (en) |
WO (1) | WO2001036000A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2491866T3 (en) | 1999-11-15 | 2014-09-08 | Piramal Healthcare (Canada) Limited | Temperature-controlled, pH-dependent, self-gelling aqueous biopolymer solution |
ATE243049T1 (en) | 1999-12-09 | 2003-07-15 | Biosyntech Canada Inc | MINERAL-POLYMER HYBRID COMPOSITION |
US20030158302A1 (en) | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
DK1294414T3 (en) | 2000-06-29 | 2006-07-24 | Biosyntech Canada Inc | Preparation and method of healing and regenerating cartilage and other tissues |
US6989373B2 (en) * | 2000-11-15 | 2006-01-24 | Bio Syntech Canada Inc. | Method for restoring a fat-pad |
US20040091540A1 (en) * | 2000-11-15 | 2004-05-13 | Desrosiers Eric Andre | Method for restoring a damaged or degenerated intervertebral disc |
CA2429165A1 (en) * | 2000-11-15 | 2002-05-23 | Bio Syntech Canada Inc. | Filler composition for soft tissue augmentation and reconstructive surgery |
US7202091B2 (en) | 2001-04-11 | 2007-04-10 | Inlight Solutions, Inc. | Optically similar reference samples |
WO2004050100A1 (en) * | 2002-12-03 | 2004-06-17 | Bio Syntech Canada Inc. | Method for treating a tumor using a thermo-gelling chitosan composition |
GB2408937A (en) * | 2003-12-09 | 2005-06-15 | Johnson & Johnson Medical Ltd | pH dependent medicinal compositions |
GB0403938D0 (en) * | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
WO2007051311A1 (en) * | 2005-11-04 | 2007-05-10 | Bio Syntech Canada Inc. | Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state |
JP5474353B2 (en) | 2005-12-23 | 2014-04-16 | ラボラトワール メディドム エス. エー. | Thermoplastic neutralized chitosan composition to form a hydrogel, lyophilizate, and method for producing them |
BRPI1009422B1 (en) | 2009-03-10 | 2019-10-01 | Elastagen Pty Ltd | INJECTABLE BIOMATERIALS |
US8506972B2 (en) | 2010-08-27 | 2013-08-13 | Oligo Medic Inc | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions |
PT2609149E (en) * | 2010-08-27 | 2015-11-20 | Oligo Medic Inc | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions |
CN103459439B (en) * | 2010-12-15 | 2017-09-12 | 金斯顿女王大学 | Use the system and method for the water with convertible ionic strength |
US9546235B2 (en) | 2011-12-19 | 2017-01-17 | The University Of Sydney | Peptide-hydrogel composite |
WO2014063194A1 (en) | 2012-10-23 | 2014-05-01 | The University Of Sydney | Elastic hydrogel |
KR102398811B1 (en) | 2012-12-10 | 2022-05-16 | 앨러간 파마슈티컬스 인터내셔널 리미티드 | Scalable three-dimensional elastic construct manufacturing |
AU2014306362B2 (en) | 2013-08-13 | 2019-04-18 | Allergan Pharmaceuticals International Limited | Regeneration of damaged tissue |
US11219639B2 (en) | 2015-07-24 | 2022-01-11 | Trimph Ip Pty Ltd | Antiseptic polymer and synthesis thereof |
ES2907686T3 (en) | 2015-11-03 | 2022-04-26 | Zoetis Services Llc | Sol-gel polymeric compounds and their uses |
US9655842B1 (en) | 2015-12-04 | 2017-05-23 | Covidien Lp | Injectable non-aqueous compositions and methods of treating vascular disease |
CN110536679B (en) | 2017-04-20 | 2023-03-31 | 硕腾服务有限责任公司 | Veterinary compositions for treating mastitis and related methods |
CN111629766A (en) | 2017-12-01 | 2020-09-04 | 硕腾服务有限责任公司 | Hydrogel composition and use thereof |
CN109957150A (en) * | 2017-12-25 | 2019-07-02 | 成都昕才医药科技有限公司 | A kind of preparation method of temperature-sensitive hydrogel precursor |
CN109957115A (en) * | 2017-12-25 | 2019-07-02 | 成都昕才医药科技有限公司 | A kind of temperature-sensitive hydrogel |
CN109957116A (en) * | 2017-12-25 | 2019-07-02 | 成都昕才医药科技有限公司 | A kind of gel rubber material of phase transformation repeatedly |
CN108853599B (en) * | 2018-07-27 | 2021-03-05 | 王宇清 | Oxygen-enriched temperature-sensitive hydrogel and preparation method thereof |
CN110388199B (en) * | 2019-06-18 | 2021-06-01 | 中国石油天然气股份有限公司 | Large-discharge-capacity composite acid fracturing modification method for carbonate reservoir |
CN111603441B (en) * | 2020-07-01 | 2022-11-25 | 瑞希(重庆)生物科技有限公司 | Amphiphilic polyamino acid copolymer/poloxamer thermo-sensitive gel and preparation method thereof |
CN114349983A (en) * | 2022-01-10 | 2022-04-15 | 深圳市勇粒生物科技有限公司 | Anti-inflammatory and bactericidal amino acid hydrogel and preparation method and application thereof |
Family Cites Families (168)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2976574A (en) | 1956-07-31 | 1961-03-28 | Union Carbide Corp | Chemical process and product |
US3266906A (en) | 1962-12-13 | 1966-08-16 | Kelco Co | Algin gel and gelatin composition having high bloom strength and process |
US3586654A (en) | 1969-04-15 | 1971-06-22 | Nat Distillers Chem Corp | Process for the preparation of polymer powders of controlled particle shape,size and size distribution and product |
US3755558A (en) | 1971-02-23 | 1973-08-28 | Du Pont | Polylactide drug mixtures for topical application atelet aggregation |
IT1021282B (en) | 1973-10-11 | 1978-01-30 | Basf Ag | PROCESS FOR THE PREPARATION OF POLYESTERIMIDE DISPERSIONS |
US4060081A (en) | 1975-07-15 | 1977-11-29 | Massachusetts Institute Of Technology | Multilayer membrane useful as synthetic skin |
US4185618A (en) | 1976-01-05 | 1980-01-29 | Population Research, Inc. | Promotion of fibrous tissue growth in fallopian tubes for female sterilization |
US4097935A (en) | 1976-07-21 | 1978-07-04 | Sterling Drug Inc. | Hydroxylapatite ceramic |
US4195175A (en) | 1978-01-03 | 1980-03-25 | Johnson Edwin L | Process for the manufacture of chitosan |
US4337760A (en) | 1978-10-13 | 1982-07-06 | Adolf Schwimmer | Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals |
JPS5943041B2 (en) | 1979-02-16 | 1984-10-19 | 大日精化工業株式会社 | Sugar derivative having urea group and method for producing the same |
US4391909A (en) | 1979-03-28 | 1983-07-05 | Damon Corporation | Microcapsules containing viable tissue cells |
US4254207A (en) | 1979-12-26 | 1981-03-03 | Hercules Incorporated | Process for producing spherical particles or crystalline polymers |
US4933105A (en) | 1980-06-13 | 1990-06-12 | Sandoz Pharm. Corp. | Process for preparation of microspheres |
DE3026762C2 (en) | 1980-07-15 | 1985-04-25 | Akzo Gmbh, 5600 Wuppertal | Process for the production of porous, pulverulent polypropylene and use of the process products |
US4394373A (en) | 1981-04-06 | 1983-07-19 | Malette William Graham | Method of achieving hemostasis |
US4532134A (en) | 1981-04-06 | 1985-07-30 | Malette William Graham | Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound |
US4424346A (en) | 1981-06-04 | 1984-01-03 | Canadian Patents And Development Ltd. | Derivatives of chitins, chitosans and other polysaccharides |
SE441009B (en) | 1982-03-08 | 1985-09-02 | Kjell Nilsson | WAY TO IMMOBILIZE LIVING BIOMATERIAL IN PEARLY POLYMERS |
US4605623A (en) | 1982-11-08 | 1986-08-12 | Malette William Graham | Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture |
US4474769A (en) | 1983-05-13 | 1984-10-02 | Pfanstiehl Laboratories, Inc. | Chitosan as a contraceptive |
US4568559A (en) | 1984-02-06 | 1986-02-04 | Biotek, Inc. | Composite core coated microparticles and process of preparing same |
US4659700A (en) | 1984-03-02 | 1987-04-21 | Johnson & Johnson Products, Inc. | Chitosan-glycerol-water gel |
US4722948A (en) | 1984-03-16 | 1988-02-02 | Dynatech Corporation | Bone replacement and repair putty material from unsaturated polyester resin and vinyl pyrrolidone |
US4731081A (en) | 1984-09-11 | 1988-03-15 | Mentor Corporation | Rupture-resistant prosthesis with creasable shell and method of forming same |
US4902792A (en) | 1985-04-19 | 1990-02-20 | Kanebo Ltd. | Fine cellulose particles and process for production thereof |
US4678470A (en) | 1985-05-29 | 1987-07-07 | American Hospital Supply Corporation | Bone-grafting material |
US4895724A (en) | 1985-06-07 | 1990-01-23 | Pfizer Inc. | Chitosan compositions for controlled and prolonged release of macromolecules |
JPS624702A (en) | 1985-06-28 | 1987-01-10 | Lion Corp | Production of water-soluble acrylated chitosan |
US6005161A (en) | 1986-01-28 | 1999-12-21 | Thm Biomedical, Inc. | Method and device for reconstruction of articular cartilage |
US5902741A (en) | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US4877775A (en) | 1986-06-16 | 1989-10-31 | E. I. Du Pont De Nemours And Company | Polymeric aminosaccharides as antihypercholesterolemic agents |
US4803075A (en) | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
US5989579A (en) * | 1986-10-02 | 1999-11-23 | Escalon Medical Corp. | Ocular insert with anchoring protrusions |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
JPH01104305A (en) | 1987-10-15 | 1989-04-21 | Tadashi Uragami | Membrane for separating liquid |
US4861627A (en) | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
EP0436499B1 (en) | 1987-07-10 | 1996-10-09 | Asahi Kogaku Kogyo Kabushiki Kaisha | A process for producing a calcium phosphate type powder |
US6610669B1 (en) | 1987-09-18 | 2003-08-26 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
GB8803697D0 (en) | 1988-02-17 | 1988-03-16 | Deltanine Research Ltd | Clinical developments using amniotic membrane cells |
JPH0228112A (en) * | 1988-04-21 | 1990-01-30 | Kaken Pharmaceut Co Ltd | Intraocular tension regulator for instillation |
US4956350A (en) | 1988-08-18 | 1990-09-11 | Minnesota Mining And Manufacturing Company | Wound filling compositions |
US5843156A (en) | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4911926A (en) | 1988-11-16 | 1990-03-27 | Mediventures Inc. | Method and composition for reducing postsurgical adhesions |
US5126141A (en) | 1988-11-16 | 1992-06-30 | Mediventures Incorporated | Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides |
US5073202A (en) | 1989-03-09 | 1991-12-17 | Micro Vesicular Systems, Inc. | Method of using a biodegradable superabsorbing sponge |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
WO1991001720A1 (en) | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
JPH0678372B2 (en) | 1990-06-19 | 1994-10-05 | 信越化学工業株式会社 | Solution for preventing adhesion of polymer scale and method for preventing adhesion of polymer scale |
GB2246514B (en) | 1990-08-01 | 1993-12-15 | Scras | Sustained release pharmaceutical compositions and the preparation of particles for use therein |
US5071644A (en) | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
US5047055A (en) | 1990-12-21 | 1991-09-10 | Pfizer Hospital Products Group, Inc. | Hydrogel intervertebral disc nucleus |
US5226326A (en) * | 1991-05-31 | 1993-07-13 | Environmental Stress Screening Corp. | Vibration chamber |
WO1993000100A2 (en) * | 1991-06-24 | 1993-01-07 | Carrington Laboratories, Inc. | Wound cleanser |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
GB2261672A (en) | 1991-11-18 | 1993-05-26 | Michael Braden | The use of biomaterials for tissue repair |
IL100096A (en) | 1991-11-20 | 1996-03-31 | Univ Ramot | Method for entrapment of active materials in chitosan |
US5658593A (en) | 1992-01-16 | 1997-08-19 | Coletica | Injectable compositions containing collagen microcapsules |
US5306305A (en) * | 1992-01-31 | 1994-04-26 | Etex Corporation | Methods of coating implants with bony structure |
US5204382A (en) | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
US5708152A (en) | 1992-03-27 | 1998-01-13 | Ciba Specialty Chemicals Corporation | N-substituted chitosan derivatives in a process for their preparation |
FR2692147B1 (en) | 1992-06-15 | 1995-02-24 | Centre Nat Rech Scient | Bioresorbable polymer microspheres free of surfactant, their preparation and their use as medicaments. |
US5266326A (en) | 1992-06-30 | 1993-11-30 | Pfizer Hospital Products Group, Inc. | In situ modification of alginate |
US5871985A (en) | 1992-09-28 | 1999-02-16 | Brown University Research Foundation | Particulate non cross-linked chitosan core matrices for encapsulated cells |
US5709854A (en) | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
GB9310030D0 (en) | 1993-05-15 | 1993-06-30 | Scras | Dry processed particles and process for the preparation of the same |
US5368051A (en) | 1993-06-30 | 1994-11-29 | Dunn; Allan R. | Method of regenerating articular cartilage |
CA2130295A1 (en) | 1993-08-26 | 1995-02-27 | Richard A. Berg | Ionically crosslinked glycosaminoglycan gels for soft tissue augmentation and drug delivery |
US5531716A (en) | 1993-09-29 | 1996-07-02 | Hercules Incorporated | Medical devices subject to triggered disintegration |
US6743783B1 (en) | 1993-12-01 | 2004-06-01 | Marine Polymer Technologies, Inc. | Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine |
US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
US6251137B1 (en) | 1994-03-23 | 2001-06-26 | Mcghan Medical Corporation | Synthetic triglyceride filler material for surgically implanted prostheses |
US5626861A (en) | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
US5723331A (en) | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
WO1995033421A1 (en) | 1994-06-06 | 1995-12-14 | Case Western Reserve University | Biomatrix for tissue regeneration |
EP0717630A1 (en) | 1994-07-08 | 1996-06-26 | SULZER Medizinaltechnik AG | Method of manufacturing implant materials |
AU3274895A (en) | 1994-07-18 | 1996-02-16 | Gel Sciences, Inc. | Novel polymer gel networks and methods of use |
SE9402528D0 (en) | 1994-07-19 | 1994-07-19 | Astra Ab | Hard tissue stimulant with electricity |
SE9402531L (en) | 1994-07-19 | 1996-01-20 | Medicarb Ab | wound healing agent |
US5510102A (en) | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5749874A (en) | 1995-02-07 | 1998-05-12 | Matrix Biotechnologies, Inc. | Cartilage repair unit and method of assembling same |
US6080194A (en) | 1995-02-10 | 2000-06-27 | The Hospital For Joint Disease Orthopaedic Institute | Multi-stage collagen-based template or implant for use in the repair of cartilage lesions |
US5906934A (en) | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
NL9500580A (en) | 1995-03-27 | 1996-11-01 | Hollandse Signaalapparaten Bv | Phased array antenna equipped with a calibration network. |
US5620706A (en) | 1995-04-10 | 1997-04-15 | Universite De Sherbrooke | Polyionic insoluble hydrogels comprising xanthan and chitosan |
US5676976A (en) | 1995-05-19 | 1997-10-14 | Etex Corporation | Synthesis of reactive amorphous calcium phosphates |
WO1996039202A1 (en) | 1995-06-06 | 1996-12-12 | Osteogenics Inc. | Biocompatible hydroxyapatite formulations and uses therefor |
US5655546A (en) | 1995-06-07 | 1997-08-12 | Halpern; Alan A. | Method for cartilage repair |
EP0830381A4 (en) | 1995-06-09 | 2000-11-22 | William N Drohan | Chitin hydrogels, methods of their production and use |
JP3881707B2 (en) | 1995-07-20 | 2007-02-14 | 学校法人松本歯科大学 | Method for producing osteogenesis promoter and method for producing osteogenic composition using osteogenesis promoter |
US5900238A (en) | 1995-07-27 | 1999-05-04 | Immunex Corporation | Vaccine delivery system |
TW389694B (en) | 1995-08-17 | 2000-05-11 | Novartis Ag | Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics |
WO1997017038A1 (en) | 1995-11-09 | 1997-05-15 | University Of Massachusetts | Tissue re-surfacing with hydrogel-cell compositions |
EP0868505B1 (en) | 1995-11-16 | 2005-02-02 | Case Western Reserve University | In vitro chondrogenic induction of human mesenchymal stem cells |
JPH09143093A (en) | 1995-11-17 | 1997-06-03 | Hoechst Japan Ltd | Cartilage/bone-inductive restoring material |
JP4193917B2 (en) | 1995-12-18 | 2008-12-10 | アンジオデバイス インターナショナル ゲーエムベーハー | Crosslinked polymer composition and method of use thereof |
US6200606B1 (en) | 1996-01-16 | 2001-03-13 | Depuy Orthopaedics, Inc. | Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration |
US5842477A (en) | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
JP2000506182A (en) * | 1996-03-13 | 2000-05-23 | ラボラトワール・メルク・シヤルプ・エ・ドーム―シブレ・エス・エヌ・セー | Liquid-gel phase transition type eye drop composition |
AU725654B2 (en) | 1996-05-03 | 2000-10-19 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
IL118376A0 (en) | 1996-05-22 | 1996-09-12 | Univ Ben Gurion | Polysaccharide sponges for cell culture and transplantation |
US5830503A (en) | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
US6060534A (en) | 1996-07-11 | 2000-05-09 | Scimed Life Systems, Inc. | Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties |
US6649192B2 (en) | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
US5964807A (en) | 1996-08-08 | 1999-10-12 | Trustees Of The University Of Pennsylvania | Compositions and methods for intervertebral disc reformation |
US6706690B2 (en) | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
US7320962B2 (en) | 1996-08-27 | 2008-01-22 | Baxter International Inc. | Hemoactive compositions and methods for their manufacture and use |
AU4941297A (en) | 1996-11-15 | 1998-06-10 | Dumex-Alpharma A/S | A method for promoting tissue repair |
JPH10158188A (en) * | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | Composition for treating cornea |
US5866415A (en) | 1997-03-25 | 1999-02-02 | Villeneuve; Peter E. | Materials for healing cartilage and bone defects |
WO1999004720A1 (en) | 1997-07-11 | 1999-02-04 | Reprogenesis Inc. | Repair of intervertebral disks |
CA2212300A1 (en) * | 1997-08-04 | 1999-02-04 | Abdellatif Chenite | In vitro or in vivo gelfying chitosan and therapeutic uses thereof |
US6110209A (en) | 1997-08-07 | 2000-08-29 | Stone; Kevin R. | Method and paste for articular cartilage transplantation |
US20020068048A1 (en) | 1997-09-05 | 2002-06-06 | Patrick A. Dreyfus | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues |
US6417247B1 (en) | 1997-10-14 | 2002-07-09 | Beth L. Armstrong | Polymer/ceramic composites |
CA2219399A1 (en) | 1997-10-24 | 1999-04-24 | Bio Syntech Ltd. | Bulk formation of monolithic polysaccharide-based hydrogels |
JP2001521786A (en) | 1997-10-30 | 2001-11-13 | ザ ジュネラル ホスピタル コーポレーション | Adhesion of cartilage matrix using isolated chondrocytes |
US6911212B2 (en) | 1998-02-27 | 2005-06-28 | Musculoskeletal Transplant Foundation | Malleable putty and flowable paste with allograft bone having residual calcium for filling bone defects |
EP1056413A4 (en) | 1998-02-27 | 2003-08-20 | Bioelastics Res Ltd | Injectable implants for tissue augmentation and restoration |
US7019192B2 (en) | 1998-02-27 | 2006-03-28 | Musculoskeletal Transplant Foundation | Composition for filling bone defects |
US7045141B2 (en) | 1998-02-27 | 2006-05-16 | Musculoskeletal Transplant Foundation | Allograft bone composition having a gelatin binder |
DE19810965A1 (en) | 1998-03-13 | 1999-09-16 | Aventis Res & Tech Gmbh & Co | Nanoparticles comprising polyelectrolyte complex of polycation, polyanion and biologically active agent, especially useful for controlled drug release on oral administration |
US6179872B1 (en) | 1998-03-17 | 2001-01-30 | Tissue Engineering | Biopolymer matt for use in tissue repair and reconstruction |
WO1999047186A1 (en) | 1998-03-18 | 1999-09-23 | University Of Pittsburgh | Chitosan-based composite materials containing glycosaminoglycan for cartilage repair |
US20030147860A1 (en) | 2002-02-07 | 2003-08-07 | Marchosky J. Alexander | Compositions and methods for forming and strengthening bone |
DE19817698A1 (en) | 1998-04-22 | 1999-10-28 | Jan Zoellner | Composition used for flat disk implant, especially nucleus pulposus implant |
JP3686335B2 (en) | 1998-07-13 | 2005-08-24 | ユニヴァースティ オブ サザーン カリフォルニア | Methods for promoting bone and cartilage growth and repair |
CZ20012782A3 (en) | 1999-02-01 | 2002-01-16 | Genetics Institute, Inc. | Composition for healing and replacement of articular cartilage |
WO2000048550A2 (en) | 1999-02-16 | 2000-08-24 | Sulzer Biologics, Inc. | Device and method for regeneration and repair of cartilage lesions |
US6436143B1 (en) | 1999-02-22 | 2002-08-20 | Anthony C. Ross | Method and apparatus for treating intervertebral disks |
AU5311700A (en) | 1999-06-01 | 2000-12-28 | Closys Corporation | Clotting cascade initiating apparatus and methods of use |
WO2001000792A1 (en) | 1999-06-29 | 2001-01-04 | Marchosky J Alexander | Compositions and methods for forming and strengthening bone |
US6429013B1 (en) | 1999-08-19 | 2002-08-06 | Artecel Science, Inc. | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
ES2491866T3 (en) | 1999-11-15 | 2014-09-08 | Piramal Healthcare (Canada) Limited | Temperature-controlled, pH-dependent, self-gelling aqueous biopolymer solution |
US20030158302A1 (en) | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
ATE243049T1 (en) | 1999-12-09 | 2003-07-15 | Biosyntech Canada Inc | MINERAL-POLYMER HYBRID COMPOSITION |
US20050244393A1 (en) | 1999-12-22 | 2005-11-03 | Henogen S.A. | Sealant or tissue generating product |
DK1294414T3 (en) | 2000-06-29 | 2006-07-24 | Biosyntech Canada Inc | Preparation and method of healing and regenerating cartilage and other tissues |
US6866866B1 (en) | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
US20040047892A1 (en) | 2000-11-15 | 2004-03-11 | Desrosiers Eric Andre | Filler composition for soft tissue augmentation and reconstructive surgery |
US20040091540A1 (en) | 2000-11-15 | 2004-05-13 | Desrosiers Eric Andre | Method for restoring a damaged or degenerated intervertebral disc |
US6756363B1 (en) | 2000-11-17 | 2004-06-29 | Wound Healing Of Oklahoma, Inc. | Solutions and films of glycated chitosan |
US20060263401A1 (en) | 2001-07-13 | 2006-11-23 | Flow Focusing, Inc. | Formulation and Method for Preventing Infection |
DE60208042T2 (en) | 2001-08-14 | 2006-08-17 | Medipost, Co., Ltd. | COMPOSITION FOR TREATING DAMAGE TO THE CORRUPT |
US6632468B2 (en) * | 2001-08-16 | 2003-10-14 | Kerry Inc. | Controlled-viscosity food flavoring system |
US8740973B2 (en) | 2001-10-26 | 2014-06-03 | Icon Medical Corp. | Polymer biodegradable medical device |
ES2357889T3 (en) | 2001-11-15 | 2011-05-03 | Piramal Healthcare (Canada) Limited | COMPOSITION AND METHOD TO RETICULATE OR MODIFY HOMOGENALLY CHITOSANE IN NEUTRAL CONDITIONS. |
US20050004057A1 (en) | 2001-12-14 | 2005-01-06 | Isabelle Boucher | Chitosan oligosaccharides and uses thereof |
TWI245634B (en) | 2001-12-28 | 2005-12-21 | Ind Tech Res Inst | Preparation of a biodegradable thermal-sensitive gel system |
US7514249B2 (en) | 2002-04-18 | 2009-04-07 | The University Of Florida Research Foundation, Inc. | Biomimetic organic/inorganic composites |
US20060204544A1 (en) | 2002-05-20 | 2006-09-14 | Musculoskeletal Transplant Foundation | Allograft bone composition having a gelatin binder |
MXPA05001242A (en) | 2002-07-31 | 2005-06-08 | Alza Corp | Injectable depot compositions and uses thereof. |
ES2321505T3 (en) | 2002-07-31 | 2009-06-08 | Alza Corporation | COMPOSITIONS OF MULTIMODAL POLYMER DEPOSIT INJECTABLE AND USE OF THE SAME. |
AU2002330762B2 (en) | 2002-09-30 | 2007-08-09 | Regen Biotech, Inc. | Composition for stimulating bone-formation and bone consolidation |
BR0315304A (en) | 2002-11-06 | 2005-08-16 | Alza Corp | Depot formulations for controlled release |
GB0302738D0 (en) | 2003-02-06 | 2003-03-12 | Advanced Biopolymers As | Composition |
US7217294B2 (en) | 2003-08-20 | 2007-05-15 | Histogenics Corp. | Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof |
GB0403938D0 (en) | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
US20060004189A1 (en) | 2004-07-02 | 2006-01-05 | James Gandy | Compositions for treating wounds and processes for their preparation |
US20060062768A1 (en) | 2004-09-23 | 2006-03-23 | Olexander Hnojewyj | Biocompatible hydrogel compositions |
ITRM20040539A1 (en) | 2004-11-02 | 2005-02-02 | Mavi Sud S R L | PREPARE WITH CHITIN OR ITS DERIVATIVES FOR COSMETIC OR MEDICAL USE. |
WO2007127795A2 (en) | 2006-04-25 | 2007-11-08 | Bumgardner Joel D | Chitosan/nanocrystalline hydroxyapatite composite microsphere-based scaffolds |
CA2672936A1 (en) | 2006-11-30 | 2008-06-05 | Bio Syntech Canada Inc. | Method for in situ solidification of blood-polymer compositions for regenerative medicine and cartilage repair applications |
US8153612B2 (en) | 2006-12-11 | 2012-04-10 | Chi2Gel Ltd. | Injectable chitosan mixtures forming hydrogels |
US7776840B2 (en) | 2007-02-21 | 2010-08-17 | Cutanea Life Sciences, Inc. | Methods of use of biomaterial and injectable implant containing biomaterial |
-
2000
- 2000-11-10 ES ES00975711.3T patent/ES2491866T3/en not_active Expired - Lifetime
- 2000-11-10 AU AU13753/01A patent/AU1375301A/en not_active Abandoned
- 2000-11-10 EP EP00975711.3A patent/EP1229940B1/en not_active Expired - Lifetime
- 2000-11-10 CA CA2685349A patent/CA2685349C/en not_active Expired - Lifetime
- 2000-11-10 WO PCT/CA2000/001341 patent/WO2001036000A1/en active Application Filing
- 2000-11-10 CA CA2427938A patent/CA2427938C/en not_active Expired - Lifetime
- 2000-11-10 DK DK00975711.3T patent/DK1229940T3/en active
-
2009
- 2009-10-09 US US12/576,354 patent/US8920842B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1229940A1 (en) | 2002-08-14 |
AU1375301A (en) | 2001-05-30 |
CA2427938C (en) | 2010-02-16 |
CA2685349C (en) | 2013-09-17 |
WO2001036000A1 (en) | 2001-05-25 |
US20100028434A1 (en) | 2010-02-04 |
CA2685349A1 (en) | 2001-05-25 |
DK1229940T3 (en) | 2014-08-18 |
ES2491866T3 (en) | 2014-09-08 |
US8920842B2 (en) | 2014-12-30 |
EP1229940B1 (en) | 2014-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2427938A1 (en) | Novel temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution, composition and preparation thereof | |
Kisiel et al. | Improving the osteogenic potential of BMP-2 with hyaluronic acid hydrogel modified with integrin-specific fibronectin fragment | |
CA2572964C (en) | Purified amphiphilic peptide compositions and uses thereof | |
EP2773696B1 (en) | Self-assembled composite ultrasmall peptide-polymer hydrogels | |
KR101637431B1 (en) | Cell-supporting body and bone regeneration material | |
Borrelli et al. | Injectable disc-derived ECM hydrogel functionalised with chondroitin sulfate for intervertebral disc regeneration | |
EP2513294B1 (en) | Scaffolds formed from polymer-protein conjugates, methods of generating same and uses thereof | |
CA2629897A1 (en) | Novel hydrogels and uses thereof | |
Lin et al. | An injectable extracellular matrix for the reconstruction of epidural fat and the prevention of epidural fibrosis | |
US20160243282A1 (en) | Shape-memory sponge hydrogel biomaterial | |
CN112980001B (en) | Collagen composite hyaluronic acid gel, extracellular matrix bionic material and preparation method | |
Seo et al. | Hyaluronate-alginate hybrid hydrogels prepared with various linkers for chondrocyte encapsulation | |
CN111432853A (en) | Cross-linked protein foams and methods of using the same | |
Onder et al. | Self-assembled silk fibroin hydrogels: From preparation to biomedical applications | |
US10434215B2 (en) | Compositions comprising a polymer-protein conjugate and an environmentally-responsive polymer and uses thereof | |
Chen et al. | Fabricating a novel HLC-hBMP2 fusion protein for the treatment of bone defects | |
CN115521371A (en) | Recombinant humanized type III collagen, preparation method and application | |
DE102015000363A1 (en) | New modular functionalizable peptide hydrogels | |
KR101796914B1 (en) | Polymer composite for filler comprising collagen and dialdehyde starch | |
JP2017528296A (en) | Composition comprising glycosaminoglycan and protein | |
RU2695343C2 (en) | Fgf-18 composition in xyloglucan gels | |
Altan | Development and characterization of biomimetic peptide-based bioink for dental tissue engineering | |
EP3868779A1 (en) | Composition based on recombinant biopolymers and uses of same as bio-ink | |
ES2705602T3 (en) | Compositions of purified amphiphilic peptides and uses thereof | |
Leeuwenburgh et al. | Genetically engineered silk–inspired protein for biomedical applications: production, characterization and evaluation of cellular response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20201110 |
|
MKEX | Expiry |
Effective date: 20201110 |